RxDoctor Payments Data

Hadi Mahmaljy, MD

Interventional Cardiology · Tampa, FLNPI 1336521830

Payments from drug & device makers

$39,897in general payments, 2019–2025

Across 405 payments — averaging $98.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$32K
  • W. L. Gore & Associates, Inc.$1K
  • Pfizer$536
  • AstraZeneca$510
  • Abbott$462
  • Inari Medical, Inc.$446
  • plus $4K from 38 others

What the payments were for

  • Consulting fees$2641%
  • Speaking & faculty fees$10,72527%
  • Travel & lodging$17,73944%
  • Food & beverage$11,01128%
  • Education$1590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,897 in reported general payments places this provider in the 75th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$700,853
Medicare patients
1,783
Services billed
5,310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban379$393,099
XareltoRivaroxaban184$225,671
JardianceEmpagliflozin46$62,660
EntrestoSacubitril/Valsartan40$58,354
Repatha SureclickEvolocumab32$37,774
FarxigaDapagliflozin Propanediol29$33,489
MultaqDronedarone Hcl24$27,845
VerquvoVericiguat22$20,687
OzempicSemaglutide18$18,434
Repatha PushtronexEvolocumab19$15,618
Praluent PenAlirocumab14$12,725
NexlizetBempedoic Acid/Ezetimibe18$11,949
Propafenone Hcl ErPropafenone Hcl33$9,191
Dabigatran EtexilateDabigatran Etexilate Mesylate25$5,182
Metoprolol Succinate322$4,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$536$393,099379 claims
Johnson & JohnsonXarelto$13$225,671184 claims
Boehringer IngelheimJardiance$196$62,66046 claims
NovartisEntresto$415$58,35440 claims
AstraZenecaFarxiga$510$33,48929 claims
Sanofi-aventis U.S. LLCMultaq$97$27,84524 claims
MerckVerquvo$260$20,68722 claims
Novo NordiskOzempic$78$18,43418 claims
Esperion Therapeutics, Inc.Nexlizet$40$11,94918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →